Today, the Greater Washington Partnership unveiled the Blueprint For Regional Mobility, the first ever CEO-driven comprehensive strategy that binds the Capital Region and better connects residents in Baltimore, Washington and Richmond to opportunity.

This unified vision for the future of the region's transportation system comes on the heels of Amazon's commitment earlier this month to bring 25,000 jobs to the region. Executing on the seven solutions and 20 actions laid out in the Blueprint will fundamentally transform the way we move around the region, reversing our current disjointed system's trajectory of worsening congestion and limiting access to essential destinations for many families in our region.


What comes to mind when you think about your body?

Most people might imagine an intricate network of blood vessels or the complex neural circuits of the brain. Or we might picture diagrams from the iconic medical textbook, Gray’s Anatomy.


With preparedness solutions that address emerging infectious diseases to chemical and biological threats, protecting and enhancing lives is at the heart of everything Emergent BioSolutions does. Emergent develops vaccines, therapeutics, and devices for some of the most notable diseases and threats in modern history, including Zika, Ebola and Anthrax.


PathSensors, Inc., a rapidly growing, Baltimore-based biotechnology company focused on delivering pathogen detection solutions, announced today that it has been awarded a $7.2 million contract from the Department of Defense – Washington Headquarters Services to provide CANARY reagents and technical support to Department of Defense Facilities in the National Capital Region. The program includes the manufacture of reagents, equipment support and the development of products for new and emerging threats. The contract extends through 2023.


Market conditions for venture funding remained very strong in the third quarter of 2018. Deal size and pre-money valuations across all equity rounds decreased slightly but still remained high by historical standards. Median pre-money valuations inched down across the board in Q3 2018. The decline in median amounts raised was more significant, with Series B financings taking the most significant hit, and with the median size falling nearly 50% from the prior quarter. However, more post-Series A financings were up rounds, reversing the decline seen in the first half of 2018.


GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. The trial’s protocol provides for administration of the investigational drug in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin), both of which are standard of care for this indication in the United States. In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GlycoMimetics for uproleselan in this patient population. The company anticipates the initiation of two complementary Phase 2/3 trials from two leading clinical consortia in early 2019.


IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from the body. Dr. Yuxing Li, Associate Professor, Department of Microbiology and Immunology, University of Maryland School of Medicine, and Fellow at the Institute for Bioscience and Biotechnology Research (IBBR), will lead the project, in collaboration with colleagues Dr. Qingsheng Li, University of Nebraska-Lincoln, and Dr. Keith Reeves, Harvard Medical School/Beth Israel Deaconess Medical Center.


Paragon Bioservices, Inc. (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, today announced it was named to Deloitte's Technology Fast 500™ for 2018, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Additionally, Paragon was named #8 to the Baltimore Business Journal's Fast 50 for the second year in a row.


There’s no doubt that now is an exciting time for health IT. Many forward-thinking software companies are applying predictive models to create solutions that can improve hospital operations and clinical outcomes. As president and CMO of a Silicon Valley-based healthcare company using data science to improve core processes in healthcare operations, I believe there are a few major elements that health IT companies must incorporate as they continue to evolve to address the needs of our trillion-dollar healthcare system. Here’s what I believe needs to happen in 2019: